Screener / SEC EDGAR /CIK 0001070494 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Acadia Pharmaceuticals Inc ACAD

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 3 Form 144 notices for $570K

10-Q, 10-K and Form 144

What ACAD's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 23, 2023 to Feb 19, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Thomas Garner
Executive Vice President and Chief Commercial Officer
Adopted 10b5-1 plan Jun 1, 2026 10-Q Aug 5, 2026
Mark C. Schneyer
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan May 28, 2026 10-Q Aug 5, 2026
James Kihara
Senior Vice President, Finance
Ended 10b5-1 plan Dec 9, 2025 10-Q Nov 5, 2026
James Kihara
Senior Vice President, Finance
Adopted 10b5-1 plan Dec 9, 2025 10-K Feb 26, 2026
Mark C. Schneyer
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan May 19, 2025 10-Q Aug 7, 2025
James Kihara
Senior Vice President, Finance
Adopted 10b5-1 plan Nov 19, 2024 10-K Feb 27, 2025
Mark C. Schneyer
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan May 30, 2024 10-Q Aug 7, 2024
Brendan P. Teehan
Executive Vice President, Chief Operating Officer and Head of Commercial
Adopted 10b5-1 plan Feb 29, 2024 10-Q Aug 7, 2024
Austin D. Kim
former Executive Vice President, General Counsel and Secretary
Adopted 10b5-1 plan Dec 15, 2023 10-K Feb 28, 2024
Stephen R. Davis
President and Chief Executive Officer
Adopted 10b5-1 plan Dec 15, 2023 10-K Feb 28, 2024
Brendan P. Teehan
Executive Vice President, Chief Operating Officer and Head of Commercial
Ended 10b5-1 plan Jul 19, 2023 10-Q Nov 3, 2023
Mark C. Schneyer
Executive Vice President and Chief Financial Officer
Adopted 10b5-1 plan May 23, 2023 10-Q Nov 3, 2023
Show the other 4 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 5, 2026 Schneyer Mark C.
Officer
5,849 $159K
Jun 26, 2026 Kihara James
Officer
11,421 $297K
May 26, 2026 JAMES K KIHARA
Officer
5,401 $114K

From the Form 144 XML filed with the SEC, since May 26, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.